Port Washington-based Pall Corp.'s liquid-filtering technology has aided nuclear power plant workers, victims of toxic bacteria in Germany, and the drought-stricken Pacific atoll of Tuvalu. Now, Pall says, it is ready to help millions of American dogs.
Specifically, it aims to help the estimated 72 million dogs -- one fifth of all U.S. canine pets -- suffering from hip joint pain and lameness. In addition to U.S. distribution, Pall typically deploys its new products globally, but it did not give an estimate of the number of osteoarthritic dogs worldwide.
A new clinical trial indicates its veterinary blood-filtering technology can relieve the symptoms of canine osteoarthritis, Pall said, disclosing the news this week at a veterinary orthopedic convention in Crested Butte, Colo.
"Dogs treated with platelet therapy from a unique filter-based process showed significant improvement from osteoarthritis-related pain and lameness according to a new study commissioned by Pall Corporation," the company said.
Pall did not provide information on the consumer cost of the platelet treatment, which it said takes about half an hour at a veterinary clinic and involves sedating the animal, drawing blood, then restoring the dogs concentrated platelets.
Pall described the study as a "two-center, prospective randomized controlled clinical trial" using, as test subjects, 20 dogs afflicted with the progressive, chronic degenerative joint disease.
Alicia L. Bertone, an Ohio State University professor and lead author of the study, said it is "the first to provide evidence in support of platelet therapy for canine osteoarthritis."
Pall's role in the technology is to supply filters for Securos canine platelet enhancement therapy, or C-PET. The Securos system, made by the veterinary supplier MWI, of Boise, Idaho, filters small amounts of a dog's own blood to produce concentrations of platelets that help heal wounds and regenerate tissue.
"This study employed both subjective questionnaires and objective measures of lameness with improvement demonstrable within C-PET treated animals that was not seen in the control groups," Michael P. Kowaleski, a Tufts University professor of orthopedic veterinary surgery who reviewed the data, said in a Pall news release.
With about 11,000 workers worldwide, Pall Corp., founded in 1949, has a market capitalization of $6.86 billion. Its shares, up 7.3 percent in the past 52 weeks, opened Friday at $61.20, at the high end of the past year's range of $39.81 to $64.55.
Read more of Inside Long Island Business